The United States of America, as represented by the Secretary, Department of Health and Human Services;Kite Pharma, Inc.
发明人:
BETTER, Marc,FELDMAN, Steven A.,ROSENBERG, Steven A.
申请号：
AU2020201292
公开号：
AU2020201292A1
申请日:
2020.02.21
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020201292A120200312.pdf#####METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF ABSTRACT Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided. Such methods may include, but are not limited to, steps of (1) enriching a population of lymphocytes obtained from a donor subject； (2) stimulating the population of lymphocytes with one or more T-cell stimulating agents to produce a population of activated T cells, wherein the stimulation is performed in a closed system using serum-free culture medium； (3) transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the cell surface receptor, using a single cycle transduction to produce a population of transduced T cells, wherein the transduction is performed in a closed system using serum-free culture medium； and (4) expanding the population of transduced T cells for a predetermined time to produce a population of engineered T cells, wherein the expansion is performed in a closed system using serum-free culture medium. Also provided herein are populations of engineered T cells produced by the methods described herein and pharmaceutical compositions thereof. AH26(24392748_1):RTK
